Aurobindo Pharma Ltd Quarterly Results

Q1 FY26-27 Results Summary

Revenue

The revenue stands at ₹9,150.35 crore, reflecting a quarter-on-quarter *(QoQ) increase of 3.35 per cent from ₹8,853.34 crore. This corresponds to a year-on-year *(YoY) growth of 16.30 per cent.

Operating Profit

Operating Profit stands at ₹1,839.34 crore, reflecting a quarter-on-quarter *(QoQ) increase of 5.08 per cent from ₹1,750.35 crore. This corresponds to a year-on-year *(YoY) growth of 14.74 per cent.

PBDT

PBDT stands at ₹2,001.91 crore, reflecting a quarter-on-quarter *(QoQ) increase of 13.15 per cent from ₹1,769.18 crore. This corresponds to a year-on-year *(YoY) growth of 24.15 per cent.

Profit Before Tax

Profit Before Tax stands at ₹1,515.09 crore, reflecting a quarter-on-quarter *(QoQ) increase of 17.39 per cent from ₹1,290.61 crore. This corresponds to a year-on-year *(YoY) growth of 25.55 per cent.

Net Profit

Net Profit stands at ₹1,032.03 crore, reflecting a quarter-on-quarter *(QoQ) increase of 12.07 per cent from ₹920.84 crore. This represents a 25.22 per cent year-on-year *(YoY) growth for the same year.

  • YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.

Aurobindo Pharma Ltd Earnings

CategoryQ1 FY26-27Q1 FY25-26Change %FY25-26FY24-25Change %
Total Revenue9,150.357,868.1416.3033,653.0831,723.736.08
Expenses7,311.016,265.1116.6926,872.6825,172.636.75
Other Income264.23107.22146.44493.61621.85-20.62
Operating Profit1,839.341,603.0314.747,274.017,172.951.41
Depreciation486.82405.7020.001,778.191,649.427.81
Interest101.6697.754.00383.97457.24-16.02
Profit Before Tax1,515.091,206.8025.555,111.855,066.290.90
Tax483.06382.6026.261,736.141,699.982.13
Net Profit1,032.03824.2025.223,502.973,483.570.56
CategoryQ1 FY26-27Q4 FY25-26Change %
Total Revenue9,150.358,853.343.35
Expenses7,311.017,102.992.93
Other Income264.23117.04125.76
Operating Profit1,839.341,750.355.08
Depreciation486.82478.571.72
Interest101.6698.213.51
Profit Before Tax1,515.091,290.6117.39
Tax483.06369.7730.64
Net Profit1,032.03920.8412.07

Aurobindo Pharma Ltd Research Reports

ActionTarget Price (₹)BrokerDateReports
Buy 1,610JM Financial23-Mar-2026
Buy 1,430Motilal Oswal04-Dec-2025
Buy 1,460Edelweiss Securities20-Jun-2025
Buy 1,387JM Financial28-May-2025
Buy 1,370Motilal Oswal28-May-2025

Aurobindo Pharma Ltd Financial Reports

Data not available.

Aurobindo Pharma Ltd Stock Prices Compare with Peers

Company1 Day1 Week1 Month3 Months6 Month1 Year
Aurobindo Pharma4.50%4.40%6.16%11.78%47.99%57.77%
Mankind Pharma0.33%-1.43%-3.40%-1.23%17.71%0.10%
Laurus Labs1.03%2.43%20.59%46.46%92.10%123.14%
Dr Reddy's Labs-0.26%0.18%-5.90%-8.42%-6.67%-3.87%
Biocon-1.71%1.65%2.76%10.12%15.93%25.71%
Alkem Lab0.38%-0.92%-0.69%0.57%-3.15%16.28%
Glenmark Pharma.-0.52%4.98%0.21%-2.69%16.90%11.67%

Aurobindo Pharma Ltd Corporate Information

Vice Chairman & Managing Director: Kambam Nityananda Reddy
Whole-time Director: M Madan Mohan Reddy
Non Executive Director: P V Ramprasad Reddy
Independent Director: Girish Paman Vanvari
Non Executive Director: P Sarath Chandra Reddy
Independent Director: Santanu Mukherjee
Chairman & Independent Director: M R Kumar
Non Executive Director: Satakarni Makkapati
Company Sec. & Compli. Officer: B Adi Reddy
Additional Director: Punita Kumar Sinha

Aurobindo Pharma Ltd News

Stocks to watch today: ITC, Maruti Suzuki, Nykaa, LIC, LG Electronics

Stocks to Watch today, May 22, 2026: Nykaa, LIC, ITC, Honasa Consumer, and Maruti Suzuki are some of the key stocks to watch today

Updated On: 22 May 2026 | 7:54 AM IST

Why pharma stocks are emerging as safe bet amid global market turmoil

The pharma sector is seen as a safe bet because demand remains steady even during inflation or economic slowdowns. Besides, companies earn revenue from multiple global markets, which helps reduce risk

Updated On: 22 May 2026 | 7:32 AM IST

Nandish Shah of HDFC Sec suggests Bear Spread on Nifty; key levels here

Nandish Shah of HDFC Securities has shared a Bear Spread strategy on Nifty, and a Bull Spread strategy on Aurobindo Pharma.

Updated On: 22 May 2026 | 7:03 AM IST

Stock picks: Analyst prefer Aurobindo Pharma, Sona BLW, Tata Steel

Stock picks: Ajit Mishra of Religare Broking recommends buying Aurobindo Pharma, Tata Steel & Sona BLW; here's why

Updated On: 14 May 2026 | 7:40 AM IST

Nifty Midcap Select index hits record high, rallies 13% in one month

The Nifty Midcap Select index hit a new high of 14,223.90, soaring 2% and surpassing its previous high of 14,118 touched on December 1, 2025.

Updated On: 06 May 2026 | 2:49 PM IST

Pharma cos brace for soft Q4; US drag persists; domestic growth cushions

Pharma sector may see a 7 per cent Y-o-Y growth in reported sales and a 1 per cent increase in Ebitda, led by steady ex-gRevlimid US sales, healthy domestic growth, and favourable forex movements

Updated On: 15 Apr 2026 | 7:57 AM IST

Ex-date alert! Aurobindo Pharma, 3 others to remain in spotlight next week

Notably, Indian equity markets will remain closed on Tuesday, April 14, on account of Dr Baba Saheb Ambedkar Jayanti.

Updated On: 10 Apr 2026 | 7:50 AM IST

Stocks to Watch today: Rate sensitives, Infosys, Aurobindo Pharma, GAIL

Stocks to Watch today, April 8, 2026: Banks, Real estate, automobiles, Infosys, Aurobindo Pharma are some of the key stocks to watch today

Updated On: 08 Apr 2026 | 7:27 AM IST

Stocks to Watch today: Godrej Consumer, Aurobindo Pharma, IRFC, PC Jeweller

Stocks to Watch today, April 7, 2025: Godrej Consumer, Aurobindo Pharma, IRFC, ACME Solar Holdings, PC Jeweller, and Titagarh Rail are some of the key stocks to watch today

Updated On: 07 Apr 2026 | 7:32 AM IST

Aurobindo Pharma sets April 12 as record date for ₹800 crore buyback

Company to repurchase up to 54.24 lakh shares at Rs 1,475 apiece through tender offer route, with promoters also eligible to participate in the buyback

Updated On: 06 Apr 2026 | 6:57 PM IST
More